Peptide AOD 9604: An Overview

Research suggests that AOD 9604 is a synthesized analog of a human hormone designed to manage obesity and assist with weight loss. Excess fat is burned when the body’s natural supply of growth hormone is supplemented in tiny amounts. But in overweight subjects, this minor component is repressed. Human growth hormone (HGH) has been changed by recreating the last 15 amino acids (177-191) as a GH Frag 177-191 peptide or AOD 9604. It ends in tyrosine and includes amino acids 177-191. [i] Unlike other anti-obesity options, researchers speculate that AOD 9604 doesn’t try to trick the body into eating less by suppressing hunger and doesn’t block the uptake of calories by making the body feel full quicker.

Research indicates that peptides like AOD 9604 suggest promise in the context of body fat and help sustain optimal Body Mass Index (BMI) levels. 

AOD 9604 Peptide Outline

In the 1990s, Professor Frank Ng of Australia’s Monash University found the AOD 9604 peptide while working to create medications with anti-obesity properties like those of Human Growth Hormone (hGH) but without the hormone’s negative adverse effects. The possible impacts of AOD 9604 on boosting metabolic rate, fat loss, lipolysis, and elevated plasma glycerol have been the subject of extensive scientific study and experimentation, the results of which are described in depth below. 

Human Growth Hormone (hGH) is a manufactured component called AOD 9604. It has been studied for its potential to activate the pituitary gland, leading to increased metabolic rate and rapid weight loss. Studies indicate that the AOD 9604 peptide seems to exert its effects via an oxidation process that is possibly autonomous of the hGH receptor, causing lipolysis and anti-lipogenesis (the suppression of fat production). [i] It has been hypothesized that this peptide may cause weight reduction with no unfavorable effects on insulin sensitivity or hunger. Data from several studies suggests that AOD 9604 might cause fat to be released from the fat cells in obese research models while inhibiting the formation of new fat and the storage of existing fat. The potential properties of this peptide, as hypothesized by numerous experimental and study studies, are outlined below.

• It may reduce overall obesity and aid in belly fat loss.
• It might set off the fat-burning process in overstuffed adipose tissue
• It could mimic the action of growth hormones in controlling adipose storage.
• It may induce lipolysis and lipogenesis suppression.
• It could not affect muscles at rest
• It may not affect insulin sensitivity and IGF-1 values.
• It may have growth hormone-like characteristics, possibly regenerating tissue and mending cartilage.

Reports from the scientific community suggest that the changed part of hGH in the AOD-9604 peptide is responsible for substantially initiating the fat-burning process without driving the production of Insulin-like Growth Factor IGF 1. In addition to affecting blood sugar levels, elevated IGF 1 levels can harm joints, the heart, and kidneys. The fact that AOD 9604 does not appear to stimulate the synthesis of IGF 1 means that all these potentially harmful effects related to IGF 1 may be avoided, making it possible that AOD-9604 could be useful in the context of conditions like osteoarthritis, osteoporosis, hypercholesterolemia, worn cartilage, and bone damage. Compared to other anti-obesity options, researchers suggest one of the main properties of AOD 9604 is that it may not alter insulin sensitivity.

AOD 9604 Peptide and Lipolytic Action 

Initial clinical trials using the AOD 9604 peptide involved a continuous presentation to fat rodents for 14 days. Results indicated that after the trial, subjects seemed to have lost both weight and fat. The higher concentration of the main lipolytic receptor ß3-AR in the adipose tissue was directly linked with these findings. 

Research purports that similar to the impacts of human growth hormone, AOD 9604 peptide may raise the suppressed levels of lipolytic receptors in fat mice compared to slender mice. Additional experiments were conducted where AOD 9604 was given to rodents with knocked-out lipolytic receptors to corroborate whether the lipolytic effects of AOD 9604 were linked with the elevated lipolytic receptor levels. Interestingly, AOD 9604 was also speculated to have worked in this situation. 

Findings imply the AOD 9604 peptide was theorized to cause a rise in energy consumption and fat metabolism, leading to lipolytic effects. In light of these findings, which suggest that AOD 9604 peptides might boost the expression of lipolytic receptors, it was determined that AOD 9604 might be useful in fat reduction regardless of the receptors. [i] The results of both the chronic and short-term studies of AOD 9604 use indicated that increased ß3-AR expression was crucial to the compound’s chronic efficacy but was not the primary judge in this response. Studies suggest that the peptide’s possible effectiveness may be attributed partly to its potential to increase oxidation and, thereby, energy consumption.

In a 2000 investigation on fat Zucker rats, the peptide AOD 9604 was given for 19 days. All rodents were hypothesized to have lost more than half their total weight compared to their placebo counterparts. There appeared to be no negative effect on the animals’ insulin sensitivity, and further research indicated that the fat tissues of the AOD 9604 animals may have had enhanced lipolytic activity.

 AOD 9604 Peptide: Conclusion

Three hundred morbidly obese test subjects participated in clinical studies performed by Metabolic Pharmaceuticals Limited in 2004. Throughout the presentation, the rate of weight reduction appeared stable. According to the study findings, research models’ lipid readings and glycemic tolerance seemed to improve marginally. This suggested that the peptide may have potential in long-term options for reducing and maintaining body weight. [ii]

References

[i] Mark Heffernan, Roger J. Summers, Anne Thorburn, Esra Ogru, Robert Gianello, Woei-Jia Jiang, Frank M. Ng, The Effects of Human GH and Its Lipolytic Fragment (AOD 9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β 3-AR Knock-Out Mice, Endocrinology, Volume 142, Issue 12, 1 December 2001, Pages 5182–5189. https://pubmed.ncbi.nlm.nih.gov/11713213/

[ii] News, Medical and Life Sciences, Obesity drug codenamed AOD 9604 highly successful in trials, 16 December 2004.